Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update

Charles River Laboratories International, Inc. (NYSE:CRL) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,000,000 shares, a drop of 7.4% from the January 15th total of 2,160,000 shares. Based on an average trading volume of 785,400 shares, the days-to-cover ratio is presently 2.5 days.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors have recently bought and sold shares of CRL. Wellington Management Group LLP raised its stake in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. D1 Capital Partners L.P. bought a new position in Charles River Laboratories International in the 4th quarter valued at $172,752,000. Norges Bank acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at $98,886,000. Allspring Global Investments Holdings LLC raised its position in shares of Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after acquiring an additional 509,163 shares during the last quarter. Finally, Nomura Holdings Inc. acquired a new position in shares of Charles River Laboratories International during the fourth quarter valued at $56,820,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CRL. TD Cowen increased their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Bank of America lowered their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Finally, StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $197.64.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL traded up $2.64 during trading hours on Tuesday, reaching $154.63. The stock had a trading volume of 1,909,962 shares, compared to its average volume of 1,001,620. The company has a market cap of $7.91 billion, a price-to-earnings ratio of 19.35, a PEG ratio of 6.47 and a beta of 1.37. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $275.00. The business’s fifty day moving average is $174.59 and its two-hundred day moving average is $189.16. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).